Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Dermapharm Holding SE sell ReynadJ

Start price
€34.60
05.08.24 / 0%
Target price
-
05.08.25
Performance (%)
-3.76%
End price
€33.30
06.08.25
Summary
This prediction ended on 06.08.25 with a price of €33.30. With a performance of -3.76%, the SELL prediction by ReynadJ was trending in the right direction. This prediction was marked as speculative and is excluded from ReynadJ's performance statistics.

Dermapharm Holding is a Munich-based pharmaceutical company that develops innovative drug formulations and medical devices. It is listed on the Frankfurt Stock Exchange and has a strong presence in Germany and Europe. The company's product portfolio includes preparations for both prescription and over-the-counter drugs, as well as medical devices used in dermatology and urology. Dermapharm Holding differentiates itself from competitors by focusing on niche markets and developing new products in-house through its research and development activities.

Performance without dividends (%)
Name 1w 1m 1y
Dermapharm Holding SE -2.611% -2.611% -1.842%
iShares Core DAX® -1.212% 1.925% 17.589%
iShares Nasdaq 100 -4.714% -1.810% 0.450%
iShares Nikkei 225® -2.976% -2.660% 10.156%
iShares S&P 500 -2.744% -0.448% 0.320%

According to ReynadJ what are the pros and cons of Dermapharm Holding SE for the foreseeable future?

Pros
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected

Comments by ReynadJ for this prediction

In the thread Dermapharm Holding SE diskutieren

Sell Dermapharm Holding SE

In the thread Trading Dermapharm Holding SE
Prediction Sell
Perf. (%) -3.76%
Target price
Change
Ends at 05.08.25

Die von ReynadJ gewählte maximale Laufzeit wurde überschritten